A Randomized Controlled Clinical Trial Comparing Belatacept with Tacrolimus after de Novo Kidney Transplantation

Transplantation

Volumn 101, Issue 10, 2017, Pages 2571-2581

  De Graav, Gretchen N ^a   Baan, Carla C ^a   Clahsen Van Groningen, Marian C ^a   Kraaijeveld, Rens ^a   Dieterich, Marjolein ^a   Verschoor, Wenda ^a   Von Der Thusen, Jan H ^a   Roelen, Dave L ^b   Cadogan, Monique ^a   Van De Wetering, Jacqueline ^a   Van Rosmalen, Joost ^a   Weimar, Wilem ^a   Hesselink, Dennis A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BELATACEPT; BIOLOGICAL MARKER; CD28 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PROGRAMMED DEATH 1 RECEPTOR; TACROLIMUS; ABATACEPT;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CELL DIFFERENTIATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BIOPSY; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ABATACEPT; ADULT; AGED; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85017439650     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001755     Document Type: Article

References (52)

1. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-termoutcomes in kidney transplantation. N Engl JMed. 2016;374:333-343.
2. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443-453.
3. Talawila N, Pengel LH. Does belatacept improve outcomes for kidney transplant recipients A systematic review. Transpl Int. 2015;28: 1251-1264.
4. Sharif A, Shabir S, Chand S, et al. Meta-analysis of calcineurin-inhibitorsparing regimens in kidney transplantation. J Am Soc Nephrol. 2011;22: 2107-2118.
5. de Graav GN, Bergan S, Baan CC, et al. Therapeutic drug monitoring of belatacept in kidney transplantation. Ther Drug Monit. 2015;37:560-567.
6. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547-557.
7. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10: 535-546.
8. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012;12:210-217.
9. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810.
10. Van Gelder T, Hesselink DA. Belatacept: A game changer Transplantation. 2016;100:1390-1392.
11. Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014;14:1817-1827.
12. Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11:66-76.
13. Wen X, Casey MJ, Santos AH, et al. Comparison of utilization and clinical outcomes for belatacept-A nd tacrolimus-based immunosuppression in renal transplant recipients. Am J Transplant. 2016;16:3202-3211.
14. Cohen JB, Eddinger KC, Forde KA, et al. Belatacept compared to tacrolimus for kidney transplantation: A propensity scorematched cohort study. Transplantation. 2016 [published online December 8 2016]. doi: 10.1097/TP.0000000000001589.
15. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes costimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009;15:746-749.
16. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant. 2011;11:22-33.
17. Xu H, Perez SD, Cheeseman J, et al. The allo-A nd viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. Am J Transplant. 2014;14:319-332.
18. Espinosa J, Herr F, Tharp G, et al. CD57(+) CD4 Tcells underlie belataceptresistant allograft rejection. Am J Transplant. 2016;16:1102-1112.
19. Mathews D, Wakwe W, Lowe M, et al. Acute rejection in non-human primates treated with belatacept is mediated by a unique CD8 memory subset. Am J Transplant. 2016;16.
20. Zhou Z, Shen J, Hong Y, et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92:251-257.
21. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009;87:926-933.
22. Participants in the International Summit on Transplant T, Organ Trafficking Convened by the Transplantation S, International Society of Nephrology in Istanbul TAM. The Declaration of Istanbul on organ trafficking and transplant tourism. Transplantation. 2008;86:1013-1018.
23. de Graav GN, Hesselink DA, Dieterich M, et al. An acute cellular rejection with detrimental outcome occurring under belatacept-based immunosuppressive therapy: An immunological analysis. Transplantation. 2016;100: 1111-1119.
24. Choy JC. Granzymes and perforin in solid organ transplant rejection. Cell Death Differ. 2010;17:567-576.
25. Abecassis M, Kaplan B. Transplantation: Biomarkers in transplantation-The devil is in the detail. Nat Rev Nephrol. 2015;11:204-205.
26. Rice TK, Schork NJ, Rao DC. Methods for handling multiple testing. Adv Genet. 2008;60:293-308.
27. van den Hoogen MW, Hesselink DA, van Son WJ, et al. Treatment of steroid-resistant acute renal allograft rejection with alemtuzumab. Am J Transplant. 2013;13:192-196.
28. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272-283.
29. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001;12: 589-597.
30. Narayanan M, Pankewycz O, El-Ghoroury M, et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. Transplantation. 2013;95: 566-572.
31. Cosio FG, Dillon JJ, Falkenhain ME, et al. Racial differences in renal allograft survival: The role of systemic hypertension. Kidney Int. 1995;47: 1136-1141.
32. Schweitzer EJ, Yoon S, Fink J, et al. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation. 1998;65:242-248.
33. Nijboer WN, Schuurs TA, van der Hoeven JA, et al. Effect of brain death on gene expression and tissue activation in human donor kidneys. Transplantation. 2004;78:978-986.
34. Bleyer AJ, Burkart JM, Russell GB, et al. Dialysis modality and delayed graft function after cadaveric renal transplantation. J Am Soc Nephrol. 1999;10:154-159.
35. Huber L, Lachmann N, Niemann M, et al. Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. Transpl Int. 2015; 28:710-719.
36. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013;9:255-265.
37. Betjes MG, Langerak AW, van der Spek A, et al. Premature aging of circulating Tcells in patients with end-stage renal disease. Kidney Int. 2011;80: 208-217.
38. Litjens NH, Huisman M, van den Dorpel M, et al. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol. 2008;19:1483-1490.
39. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
40. Mou D, Espinosa J, Lo DJ, et al. CD28 negative T cells: Is their loss our gain Am J Transplant. 2014;14:2460-2466.
41. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381:434-438.
42. Elwood ET, Larsen CP, Cho HR, et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation. 1998;65:1422-1428.
43. Cortes M, Laurie S, Sayed B, et al. Rapid emergence of CD28null cells following ex vivo restimulation is associated with belatacept resistant rejection. Am J Transplant. 2016;16.
44. Vallejo AN. CD28 extinction in human Tcells: Altered functions and the program of T-cell senescence. Immunol Rev. 2005;205:158-169.
45. Pera A, Vasudev A, Tan C, et al. CMV induces expansion of highly polyfunctional CD4+ T cell subset coexpressing CD57 and CD154. J Leukoc Biol. 2017;101:555-566.
46. Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res. 2011;157:175-179.
47. Wikby A, Maxson P, Olsson J, et al. Changes in CD8 and CD4 lymphocyte subsets, Tcell proliferation responses and non-survival in the very old: The Swedish longitudinal OCTO-immune study. Mech Ageing Dev. 1998;102: 187-198.
48. Olsson J, Wikby A, Johansson B, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: The Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187-201.
49. Bestard O, Cruzado JM, Lucia M, et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int. 2013;84: 1226-1236.
50. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
51. Hricik DE, Augustine J, Nickerson P, et al. Interferon gamma ELISPOT testing as a risk-stratifying biomarker for kidney transplant injury: Results from the CTOT-01 multicenter study. Am J Transplant. 2015; 15:3166-3173.
52. Crespo E, Roedder S, Sigdel T, et al.Molecular and functional noninvasive immune monitoring in the ESCAPE study for prediction of subclinical renal allograft rejection. Transplantation. 2016 [published online June 29 2016]. doi: 10.1097/TP.0000000000001287.